Compare GLBS & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | FEMY |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 37.2M |
| IPO Year | 2010 | 2021 |
| Metric | GLBS | FEMY |
|---|---|---|
| Price | $1.98 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | 96.9K | ★ 548.9K |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $13.06 | $183.83 |
| Revenue Next Year | $20.20 | $196.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $1.00 | $0.31 |
| 52 Week High | $2.44 | $1.29 |
| Indicator | GLBS | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 39.55 |
| Support Level | $1.51 | $0.33 |
| Resistance Level | $2.23 | $0.58 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 27.87 | 45.52 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.